Rey E, D'Athis P, Richard M O, Guerre J, Dorfman P, Bercoff E, Olive G
Int J Clin Pharmacol Ther Toxicol. 1986 Aug;24(8):408-14.
The pharmacokinetics of single intravenous (100 mg) and oral (450 mg) doses of buflomedil was studied in 3 and 6 patients respectively, suffering from chronic liver disease. Comparisons of buflomedil kinetic parameters between the patients and healthy subjects indicate a significant increase in AUC0 infinity, T beta, u' and a significant decrease in Cle', Clnr when the patients received the oral dose, but no significant differences when the patients received the intravenous dose probably due to the small number of patients explored. The elimination of buflomedil is impaired in chronic hepatic disease. It seems advisable to reduce the usual dose to half its value when the prothrombin index is around 50% associated with a low albumin concentration and a low factor V.
分别在3例和6例慢性肝病患者中研究了单次静脉注射（100毫克）和口服（450毫克）剂量丁咯地尔的药代动力学。患者与健康受试者之间丁咯地尔动力学参数的比较表明，患者口服给药时，AUC0至无穷大、Tβ、u'显著增加，Cle'、Clnr显著降低，但患者静脉给药时无显著差异，这可能是由于所研究的患者数量较少。慢性肝病患者中丁咯地尔的消除受损。当凝血酶原指数约为50%且白蛋白浓度低和V因子水平低时，似乎建议将常用剂量减半。
